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Abstract
A major problem with current anxiolytic medications is abuse liability; thus, new pharmaceutical
targets are being explored. Cannabinergic and vanilloidergic signaling is of interest in the
modulation of anxiety through cannabinoid type 1 receptor (CB1R) activation and transient
vanilloid type 1 channel (TRPV1) inhibition. Arachidonoyl serotonin (AA-5-HT), a dual fatty
acid amide hydrolase (FAAH) and TRPV1 inhibitor, and arachidonyl-2-chloro-ethylamide
(ACEA), a direct CB1R agonist, are drugs of interest in modulating these two systems. The
current study explored the addictive potential of chronic AA-5-HT or ACEA administration in
the open field (OF), during in vivo fixed potential amperometry (FPA), during conditioned place
preference (CPP), and during saccharin preference. AA-5-HT did not alter locomotor activity in
the OF, dopamine efflux in the NAc, CPP, and saccharin preference. ACEA altered dopamine
dynamics in the NAc, but did not alter locomotor activity in the OF, CPP, or saccharin
preference. These results suggest these drugs present little addictive potential.

ii

Table of Contents
Chapter

Page

List of Figures

iv

1.

Introduction
Cannabinoid System
TRPV1 Channel Activity
AA-5-HT
ACEA
Dopamine System
Cross-modulation of Cannabinoid and Dopamine Systems
Cannabinoids and Anhedonia
Current Study

1
3
5
6
7
8
10
13
14

2.

Methods
Animals
Chronic Drug Treatments
Open Field
Dopamine Recordings
Conditioned Place Preference
Two-Bottle Choice Test
Design and Statistical Analyses

14
15
15
16
17
19
20
20

3.

Results

22
22
24
24
25
28
28
29

Open Field
Dopamine Autoreceptor Sensitivity
Baseline Dopamine Recordings
Dopamine Recordings Following Drug Challenge
Stereotaxic Placement of Electrodes
Conditioned Place Preference
Two-Bottle Choice Test
4.

Discussion

30

References

36

Appendix A

48

Appendix B

60

iii

List of Figures
Figure

Page

1. Baseline locomotor activity in the OF divided into 10 min blocks

49

2. Drug challenge locomotor activity in the OF divided into 10 min blocks

50

3. Dopamine autoreceptor sensitivity

51

4. Baseline dopamine results

52

5. Percent baseline dopamine release and half-life for AA-5-HT

53

6. Percent baseline dopamine release and half-life for ACEA

54

7. Percent baseline dopamine release and half-life for cocaine

55

8. Representative coronal sections of the mouse brain

56

9. Time differences within and entries into the drug paired side

57

10. Drug challenge on distance travelled on drug-paired days

58

11. Drug challenge on saccharin preference

59

iv

Examining the Chronic Effects of Indirect and Direct Cannabinoid Receptor
Agonists on Dopamine Transmission in the Nucleus Accumbens of Mice
Uncertainty plays an integral role in human and non-human animal behaviors. Anxiety is
an anticipatory process by which animals predict aversive events or fail to recognize safety
signals, causing disinhibition of the default neurobiological stress response (Freels, Lester, &
Cook, 2019; Brosschot, Verkuil, & Thayer, 2016). Anxiety is the anticipation of future threats or
danger, leading to muscle tension and vigilance and is typically associated with an
overestimation of the danger of possible, future threats (American Psychological Association,
2013). Anxiety-related behaviors and their central nervous system underpinnings are not
inherently maladaptive. Correctly responding to a threatening situation with anxiety through
aversion or other means is paramount to the safety of any individual. However, anxiety
behaviors become problematic when such responses occur in situations that are objectively
neutral or of a lower objective threat level than perceived (Brosschot, Verkuil, & Thayer, 2016).
Anxiety disorders stem from excessive anxiety, typically lasting more than 6 months and can
have symptoms including restlessness, muscle tension, fatigue, difficulty concentrating,
irritability, incapacitation, and sleep disturbance all of which can disrupt positive relations and
performance in work, school, and everyday life (American Psychological Association, 2013).
In the United States of America, anxiety disorders have become expensive and prevalent
health issues. In 2009 and 2010, the adult population of the United States of America paid an
estimated $33 billion annually for anxiety-symptom-related treatment (Shrineshan et al., 2013).
From interviews between 2001 and 2003, it was found that anxiety symptoms affected around
18.1% of the United States of America’s adult population annually, of which 22.8% of those
suffering or 4.1% of this country’s adult population, had symptoms classified as severe (Kessler,
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Chiu, Demler, & Walters, 2005). Alleviation of these symptoms in a non-addictive way is
paramount to helping those who suffer from anxiety.
Benzodiazepines are a group of conventional anxiolytics, which are typically prescribed
for acute and chronic anxiety. Two recognizable trade name drugs that fall into this category are
Xanax and Valium. Between July 2007 and June 2008, pharmacies filled 112.8 million
prescriptions for benzodiazepines (Cascade & Kalali, 2008).

Benzodiazepines work by binding

to benzodiazepine binding pockets on γ-Aminobutyric acid receptors (GABAARs), causing
inhibition of neuronal transmission in the amygdala, which is thought to mediate brain circuits
associated with the appraisal of threat (Starcevic, 2012). Additionally, these drugs positively
modulate GABAARs on interneurons in the ventral tegmental area (VTA) causing dopamine
neurons to fire by increasing the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor/N-methyl-D-aspartate (NMDA) receptor ratio mediated frequency of miniature
excitatory synaptic currents (Braestrup & Squires, 1977; Heikkinen, Möykkynen, & Korpi, 2009;
Tan et al., 2010). The associated changes in neurotransmission may be indicative of abuse
potential. People utilizing chronic benzodiazepine treatment for anxiety are at risk for
developing dependence, which can lead to abuse, overdose, and even death (Farach et al., 2012).
Between 1996 and 2013, the rate of fatal overdoses involving benzodiazepines increased over 4fold to 3 per 100,000 adults, which is faster than the increased rate of prescriptions filled
(Bachhuber, Hennessy, Cunningham, & Starrels, 2016). Such problems limit the use of
benzodiazepines for treating chronic anxiety and have physicians seeking alternate
pharmaceuticals.
Antidepressants including selective serotonin reuptake inhibitors (SSRIs) and selective
norepinephrine reuptake inhibitors (SNRIs) are another group of conventional anxiolytics often
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used as an alternative treatment for chronic anxiety. However, this class of drugs has been
associated with high non-response rates (such as 44%) and long periods (e.g., four months)
between drug onset and therapeutic benefits (Montgomery, Sheehan, Meoni, Haudiquet, &
Hacket, 2002). Additionally, anxiety symptoms can worsen in the first two weeks of treatment
with an SSRI for patients with co-morbid major depressive disorder (Gollan et al., 2012). Such
issues lend support for the investigation of new pharmacotherapies for anxiety. The
cannabinergic system is a promising target, which could provide anxiolytic effects without the
drawbacks of benzodiazepines and antidepressants.
Cannabinoid system
The cannabinergic system consists of two primary types of cannabinoid receptors
(CBRs), type 1 (CB1Rs) and type 2 (CB2Rs), with CB1Rs being the main target for anxiolytic
effects. CB1Rs are predominately expressed in the central nervous system (CNS) where they are
found at significantly higher levels on GABAergic than glutamatergic neurons in various brain
regions (Howlett et al., 2002; Kano, Ohno-Shosaku, Hashimotodani, Uchigashima, & Watanabe,
2009). CB1Rs are concentrated in high densities in brain regions associated with the regulation
of emotional processing and behaviors related to anxiety such as the prefrontal cortex,
basolateral amygdala, and ventral hippocampus (Katona et al., 1999; Rubino et al., 2008).
Activation of glutamate receptors causes Ca2+ influx and postsynaptic neuron depolarization,
which then triggers the release of the endocannabinoids (eCBs). Specifically, N-arachidonoylethanolamide (AEA) that binds to CB1R and 2-arachidonoylglyceral (2-AG) that binds to CB1/2R
through retrograde transmission are released (Batista et al., 2014; Howlett et al., 2002; Kano et
al., 2009). AEA and 2-AG then inhibit voltage activated Ca2+ channels, inhibiting pre-synaptic
neurotransmission before being trafficked by fatty acid binding protein-5 (FABP5) and fatty acid
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binding protein-7 (FABP7) to the endoplasmic reticulum and metabolized by fatty acid amide
hydrolase (FAAH) in presynaptic terminals and monoacylglycerol lipase (MAGL) in
postsynaptic terminals respectively (Blankman & Cravatt, 2013; Dinh et al., 2002; Giang &
Cravatt, 1997; Gulyas et al., 2004; Haj-Dahmane et al., 2018; Kaczocha, Glaser, & Deutsch,
2009; Ohno-Shosaku, Maejima, & Kano, 2001; Maccarrone, 2017; Maione et al., 2007). The
modulation of cannabinergic signaling can alter behaviors and may be a target for the
development of new pharmaceuticals.
The pharmacological manipulation of the cannabinoid system can be used as a target for
anxiolytic treatment. Rodent studies indicate that pharmaceutically stimulating CB1Rs or
increasing eCB levels (via inhibition of FAAH or eCB transporters) promote anxiolytic-like
behaviors in the elevated plus maze (EPM), open field (OF), and light/dark box (LDB) (Fogaça,
Aguiar, Moreira, & Guimarães, 2012; Freels, Lester, & Cook, 2019; Hakimizadeh, Oryan,
Moghaddam, Shamsizadeh, & Roohbakhsh, 2012; Zaitone, El-Wakeil, & Abou-El-Ela, 2012).
Thus, activation of CB1Rs may be a target for the treatment of anxiety.
It is important to note that CB1R agonists act in a dose dependent manner where lower
doses are anxiolytic and higher doses can be anxiogenic (Patel & Hillard, 2006). This biphasic
effect can be attributed in part to the dose-dependent modulation of glutamatergic and
GABAergic signaling. Low doses of cannabinoids inhibit glutamatergic neurons, producing
anxiolytic effects, and high doses inhibit GABAergic neurons, producing anxiogenic effects
(Rey, Purrio, Viveros, & Lutz, 2012). These effects may be associated with the distribution or
sensitivity of the CB1Rs on each of these neuron types. CB1Rs on glutamatergic presynaptic
neuron terminals display an around 30-fold lower sensitivity to CBR agonists than those on
GABAergic presynaptic neuron terminals (Ohno-Shosaku et al., 2002; Rey, Purrio, Viveros, &
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Lutz, 2012). Additionally, downstream effects may play an integral role in this modulation. In
the amygdala, CB1R activation inhibited glutamatergic signaling (leading to depolarization
induced suppression of excitation: DSE) and GABAergic signaling (leading to depolarization
induced suppression of inhibition: DSI), both of which may be modulating factors in anxietylike behaviors (Azad et al, 2003; Kamprath et al., 2011). Therefore, in finding potential
pharmacological treatments for anxiety, it is paramount to ascertain the correct dosage in order to
prevent the inverse of the desired effect. The neuropharmacology of eCBs are further
complicated when considering other receptor types activated by eCBs.
TRPV1 channel activity
The transient receptor potential cation channel subfamily V member 1 (TRPV1) is
another target for altering neurotransmission and potentially alleviating anxiety as eCB
activation of these receptors is anxiogenic. TRPV1s are Ca2+, Mg2+, and Na+ permeable ion
channels, which are located on both presynaptic and postsynaptic neurons and are predominately
localized on glutamatergic neurons (Caterina et al., 2000; Iannotti et al., 2004; Kaur & Gibson,
2009; Marinelli et al., 2007). AEA enters the cell via the AEA membrane transporter (AMT)
where it functions as an agonist at an intracellular pocket on TRPV1, which causes an influx of
Ca2+ ions (De Petrocellis et al., 2001; Ross, 2003) . This activation of TRPV1 induces cellular
depolarization (Rosenbaum & Simon, 2007). This causes an excitatory response in the brain that
may induce anxiety and anxiety-like behaviors.
Antagonists of TRPV1s are potentially anxiolytic. For example, capsazepine, a TRPV1
antagonist, induced anxiolytic-like behaviors in the EPM (Aguiar, Terzian, Guimarães, &
Moreira, 2009; Hakimizadeh et al., 2012; Terzian, Aguiar, Guimarães, & Moreira, 2009),
suggesting the TRPV1 plays the opposite role of the CB1R in anxiety. Additionally, TRPV1
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knockout mice expressed more anxiolytic-related behaviors in LDB and EPM (Marsch et al.,
2007). Therefore, the TRPV1 may be a target for antagonism in the treatment of anxiety.
Though, the modulation of TRPV1 is complicated due to some agonists at this receptor
also agonizing CB1R. Importantly, the eCB AEA is an agonist for both CB1Rs and TRPV1s
(Kaur & Gibson, 2009; Smart et al., 2000). Additionally, exogenous CBs such as cannabidiol
(CBD) can also activate TRPV1 (Iannotti et al., 2014). Furthermore, the endogenous villanoid
N-arachidonoyl-dopamine (NADA) can bind to CB1Rs and TRPV1s located in midbrain regions
housing dopamine neurons, thus modulating dopaminergic neurotransmission important for both
anxiety and addiction (de la Mora, Gallegos-Cari, Arizmendi-Gracía, Marcellino, & Fuxe, 2010;
Marinelli et al., 2007). Additionally, CB1Rs and TRPV1s are co-localized in the nucleus
accumbens (NAc) shell (predominately) and core of mice (Micale et al, 2009). Therefore, eCBs
can modulate activity at these receptors in areas implicated in reward. This crosstalk lends
support for the utilization of TRPV1 antagonism as well as CB1R agonism as a means for
reducing anxiety-like behaviors and the development of novel anxiolytic drugs.
AA-5-HT
N-Arachidonoyl-serotonin (AA-5-HT) is a potential drug of interest in treating anxiety.
AA-5-HT is an endogenous inhibitor of FAAH catalyzed hydrolysis of AEA and antagonist of
TRPV1s (Maione et al., 2007). AA-5-HT administration in male C57BL/6J (B6) mice elicited
anxiolytic effects in the EPM and was more potent than URB597 (FAAH blocker) or SB3667791
(TRPV1 blocker) when used individually, suggesting inhibiting both the enzyme and the receptor
simultaneously is more efficacious (Micale et al., 2009). Additionally, the co-administration of
AA-5-HT and SB3667791 (TRPV1 blocker) enhanced the anxiolytic effect, which may suggest
the antagonists work in concert (Micale et al., 2009). These results were mitigated by
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administration of either a selective CB1R antagonist or a selective TRPV1 agonist; although, it
should be noted that these effects were strain specific to B6 mice and varied for Swiss mice
(Micale et al., 2009). For example, administration of 2.5 mg/kg of AA-5-HT via intraperitoneal
(i.p.) injections in Swiss mice did not significantly alter anxiolytic behaviors in the EPM when
injected either once 30 mins before testing or sub-chronically, every other day for seven days but
did induce anxiolytic behaviors in the EPM when injected chronically, every day for seven days
(Micale et al., 2009). In a study done using Sprague-Dawley rats, the administration of AA-5HT into the intra-basolateral amygdala (BLA) also produced anxiolytic effects in the EPM (John
& Currie, 2012). Furthermore, previous studies from our lab have shown that BALB/cJ (BCJ)
mice, a relatively more anxious strain, expressed moderate anxiolytic-like behaviors in the LDB
and OF after acute i.p. injections of AA-5-HT (Freels, Lester, & Cook, 2019). In vivo Fixed
potential amperometry (FPA) in B6 mice found decreased dopamine release in the NAc
following an injection of AA-5-HT, suggesting AA-5-HT is not highly rewarding, which may
mitigate the potential for abuse (Freels, Lester & Cook, 2019). The chronic administration of
AA-5-HT may alter the dopamine dynamics in the NAc via CB1R indirect agonism in a different
way than acute administration, and, thus, it is important to discern how chronically increasing the
activation of CB1Rs indirectly via AA-5-HT administration alters anxiety-related behaviors and
dopamine dynamics.
ACEA
Arachidonyl-2-chloro-ethylamide (ACEA) is another drug that increases CB1R
activation. ACEA is a selective agonist for this receptor but does have some affinity in high
concentrations for TRPV1 as a partial agonist (Casarotto et al., 2012; Price, Patwardhan,
Akopian, Hargreaves, & Flores, 2004). Administration of ACEA has been shown to moderate
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depression and anxiety-related behaviors (Freels, Lester, & Cook, 2019; Rutkowska &
Jachimczuk, 2004; Simone, Malivoire, & McCormick, 2015). ACEA administration produced
anxiolytic-like behaviors in Wistar rats in the EPM and Vogel conflict tests (VCT) (Fogaça,
Aguiar, Moreira, & Guimarães, 2012). Additionally, ACEA increased the threshold of electric
stimulation of the midbrain dorsal periaqueductal gray (PAG) required to induce panic-like
behaviors in male Wistar rats (Casarotto et al., 2012). The mechanism for this drug is related to
the regulation of CB1R signaling and glutamate transmission. ACEA agonism of CB1R
depressed evoked glutamate release (Fawley, Hofmann, & Anderson, 2014). Additionally, the
administration of ACEA prevented stress induced upregulation of CB1R mRNA and restored
excitatory amino acid transporter-2 (EAAT-2) protein expression, which prevented stress
induced reductions in glutamate uptake (García-Bueno, Caso, Pérez-Nievas, Lorenzo, & Leza,
2007; Zoppi et al., 2011). In vivo FPA in B6 mice found decreased dopamine release in the NAc
following an injection of ACEA, suggesting ACEA is not highly rewarding (Freels, Lester &
Cook, 2019). The chronic administration of ACEA may alter the dopamine dynamics in the
NAc in a different way than acute administration. Therefore, ACEA plays a role in modulating
CB1R expression, depressing glutamate and dopamine activity, and decreasing anxiety-like
behaviors.
Dopamine system
The dopamine system is comprised of morphologically and functionally differing
receptors. The main receptors for the dopamine system are divided into two categories
comprised of D1-like receptors (D1 and D5), which stimulation increases cyclic adenosine
monophosphate (cAMP), and D2-like receptors (D2, D3, and D4), which stimulation decreases
cAMP (Neve, Seamans, & Trantham-Davidson, 2004; Stoof & Kebabian, 1981). The dopamine
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D2 receptor (D2R) can be subdivided into two isoforms with distinct morphology and function,
which are the long (D2L) a postsynaptic receptor and the short (D2S) a presynaptic autoreceptor
forms (Usiello et al., 2000). The dopamine autoreceptor (DAR) on dopamine neurons are
comprised of this subdivision and modulate dopamine transmission through binding dopamine,
which cascades into regulating the expression of tyrosine hydroxylase (TH) and the plasma
membrane dopamine transporter (DAT) in the VTA (Ford, 2014). The DAT can transport
dopamine into and from the presynaptic neuron. The DAT typically transports dopamine into
the cell via a Na+/Cl- dependent mechanism (Khalig & Galli., 2005). Dopamine receptors
predominately exist in the brain along pathways associated with cognition (mesocortical
dopamine pathway), lactation (tuberoinfundibular pathway), locomotion (nigrostriatal pathway,
hypothalamospinal projection, and incertohypothalamic pathway), and reward (mesolimbic
pathway).
The mesolimbic dopamine pathway has been implicated in anxiety. This pathway is
comprised of dopamine cell bodies located in the VTA that project to the limbic system, most
notably the NAc (Wise & Bozarth, 1984). Stress-related events alter signaling in the mesolimbic
dopamine pathway. Acute, forced, and, cold swim test stress increased the AMPA/NMDA ratio
of EPSCs and thus enhanced the strength of excitatory synapses on midbrain dopamine neurons
(Saal, Dong, Bonci, & Malenka, 2003). Restraint stress increased dopamine levels in the NAc
for 40 min post-stress before returning to baseline, and release from restraint increased dopamine
levels in the NAc (Imperato, Angelucci, Casolini, Zocchi, & Puglisi-Allegra, 1992; Imperato,
Puglisi-Allegra, Casolini, & Angelucci, 1991). Social isolation stress increased anxiety-like
behaviors in the EPM and increased dopamine release and DAT activity but not DAR activity in
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the NAc core (Yorgason, España, Konstantopoulos, Weiner, & Jones, 2013). Therefore, stress
alters signaling in this pathway in a type and time-course dependent manner.
Additionally, the mesolimbic dopamine pathway has been implicated in reward and abuse
liability for posited drugs. Naturally and pharmacologically increasing dopamine transmission in
this pathway has been implicated in reward and addiction. Acute drug administration including
cocaine, amphetamine, morphine, nicotine, and ethanol enhanced the strength of excitatory
synapses on midbrain dopamine neurons like acute stress did (Saal, Dong, Bonci, & Malenka,
2003). The mesolimbic dopamine pathway’s signals are associated with the salience of predicted
cues for a reward including drugs of abuse (Berridge & Robinson, 1998; Day, Roitman,
Wightman, & Carelli, 2007; Everitt & Robbins, 2005). Seeking and taking addictive drugs
activate this pathway, and the modulation of this pathway has been implicated in the rewarding
nature of cannabinoids (Gardner, 2011; Ginovart et al., 2012). Therefore, discerning the
alterations in dopamine signaling in the mesolimbic pathway can signify the abuse liability of a
drug, which is additionally prevalent to anxiolytics as anxiety also alters dopamine signaling in
this pathway.
Cross-modulation of cannabinoid and dopamine systems
Neurotransmitters and drugs of specific receptors can alter the sensitivity, expression, and
activation of other receptors. This cross-modulation between systems plays an integral role in
the efficacy and liability of potential pharmaceuticals including anxiolytics. Therefore,
discerning and evaluating the changes in various neurotransmitter pathways grants a better
understanding of the potential off-target, especially undesired, effects from the administration of
a given drug.
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Cannabinoid administration can alter dopaminergic signaling. Chronic Δ9tetrahydracannabinol (THC) administration upregulated D3R mRNA and binding in the NAc and
D2/3R in the VTA, leading to super-sensitization, which may play a role in the rewarding and
addictive nature of this drug (Ginovart et al., 2012).

On the contrary, THC desensitizes CB1Rs

via removal by an arrestin (Morgan et al., 2014). Therefore, CB1R activation sensitizes D2/3Rs
and desensitizes CB1Rs. CB1R agonist administration attenuated dopamine release in the NAc of
mice and rats (Cheer, Wassum, Helen, Philips, & Wightman, 2004; Freels, Lester, & Cook,
2019; O’Neill, Evers-Donnelly, Nicholson, O’Boyle, & O’Connor, 2009). In male Swiss
Webster mice, rimonabant (CB1R antagonist) administration before cocaine decreased locomotor
activity and percent change in dopamine in the NAc core but not in the shell, and URB597
(FAAH blocker) administration before cocaine increased locomotor activity and percent change
in dopamine in the NAc core (Mereu et al., 2013). However, in male Sprague-Dawley rats,
WIN-55,212-2 (CB1R agonist) reduced dose-dependent increases in cocaine-induced locomotor
activity (Vlachou, Stamatopoulou, Nomikos, & Panagis, 2008). These contrary results may be
due to the biphasic effects associated with cannabinoid administration where the FAAH blocker
may have led to the inhibition of glutamatergic signaling and the direct CB1R agonist may have
led to the inhibition of GABAergic signaling. Thus, effects may differ when comparing indirect
eCB enhancers (such as FAAH blockers) and direct CB1R agonists. Cross-sensitization of the
cannabinergic system with drugs such as AA-5-HT with other neurotransmitter systems warrants
further investigation.
The cannabinoid system may still be a target for treating anxiety utilizing drugs, which
are not direct agonists of this system and may not increase dopamine in the mesolimbic
dopamine pathway. TRPV1 and FAAH have implications in dopamine modulation. Agonism
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and antagonism of TRPV1 may modulate dopamine signaling. TRPV1 agonist administration in
the VTA increases dopamine firing and concentrations in the NAc, TRPV1 antagonism coadministration prevented this increase, and these changes are caused via alterations in
glutamatergic transmission onto these neurons (Marinelli, Pascucci, Bernardi, Puglisi-Allegra, &
Mercuri, 2005). Inhibition of FAAH via URB597 alone did not increase basal levels of
dopamine or peak dopamine response, but URB597 administration followed by AEA increased
the peak dopamine response (Solinas, Justinová, Goldberg, & Tanda, 2006). This suggests the
dopaminergic effect requires the combination of the FAAH blocker and eCB AEA
administration. Previous research in our lab has shown that acute administration of AA-5-HT
decreased stimulation-evoked dopamine in the NAc of mice (Freels, Lester, & Cook, 2019).
Similarly, using microdialysis, Murillo-Rodríguez and colleagues (2017) recently showed that
AA-5-HT administration decreased the extracellular content of dopamine and reduced the
increase in extracellular dopamine caused by the administration of CBD in male Wistar rats.
Therefore, drugs that do not directly activate the CB1R but instead act in indirect ways such as
FAAH inhibition or TRPV1 antagonism may not increase dopamine release and thus may not be
rewarding.
Drugs that act on the cannabinergic system may have potential as anxiolytics but also
may carry an abuse potential. Indirect and direct modulation of this system has been posited as a
potential target for the treatment of anxiety (Freels, Lester, & Cook, 2019; Micale et al., 2009).
However, little is known about the effects of chronic administration of indirectly modulating
drugs. Investigating indirect and direct modulation of the cannabinergic system on addictionrelated behaviors and dopamine signaling, especially when chronically administered, would
determine the addictive potential of these posited pharmaceuticals.
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Cannabinoids and anhedonia
When exploring the anxiolytic potential of posited pharmaceuticals, anhedonia is of
concern. Anhedonia is a reduction in the ability to experience pleasure or a diminished interest
in pleasurable activities (American Psychological Association, 2013). A two-bottle choice test
for a sweet liquid can be utilized to explore the role of drug administration on anhedonia (Liu et
al., 2018). Dopamine signaling plays a role in anhedonia. D1R antagonist administration
attenuated the acquisition of a sucrose or fructose preference (Azzara, Bodnar, Delamater, &
Sclafani, 2001; Bernal et al., 2009; Fazilov et al., 2018; Kraft et al., 2015; Muscat & Willner,
1989) CB1R signaling also plays a role in anhedonia. CP55940 (a CB1R agonist), URB597, and
rimonabant had no effects on saccharin preference alone, but chronic mild stress-induced
reductions in sucrose preference were attenuated by CP55940 or URB597 and enhanced by
rimonabant (Bortolato et al., 2007; Rademacher & Hillard, 2007). CB1R-knockout on D1R
expressing neurons mildly reduced sucrose preference (Terzian, Drago, Wotjak, & Micale,
2011). Anhedonia-related behaviors may be associated with reductions in dopaminergic
signaling as research has shown that CB1R agonist administration attenuated dopamine release in
the NAc of mice and rats (Cheer, Wassum, Helen, Philips, & Wightman, 2004; Freels, Lester, &
Cook, 2019; O’Neill, Evers-Donnelly, Nicholson, O’Boyle, & O’Connor, 2009). Therefore,
reducing the activation of D1Rs through antagonism or through synaptic dopamine reductions by
CB1R indirect or direct agonism may lead to anhedonia.
The cannabinergic system and the dopaminergic system are linked to anxiety and reward,
and the cross-modulation of these systems require further exploration in order to assess the
anxiolytic potential of drugs that indirectly or directly agonize the cannabinergic system and to
evaluate the associated addiction- and anhedonia-related behaviors. The length of drug
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administration, the size of the dosage, the pharmacology of the posited anxiolytic, and the type of
stress all impact the interactions between these systems and their associated behaviors.
Current study
The current study explored the addictive potential of the posited anxiolytics AA-5-HT
and ACEA. Specifically, the project determined the effect of repeated AA-5-HT or ACEA
administration on NAc dopamine transmission. Mice were pretreated with a chronic, seven-day
dose of either AA-5-HT, ACEA, or vehicle (negative control). Locomotor activity and behaviors
related to addiction were assessed using the open field, and aspects of dopamine transmission
were assessed by in vivo FPA. As mentioned above, Freels and colleagues from our lab (2019)
have done similar experiments with AA-5-HT and ACEA, using only acute injections, finding
both drugs decrease NAc dopamine release. The current study is more generalizable compared
to our previous study by using dosing more applicable to the human population (chronic use).
Chronic administration of these drugs also allows us to address the aforementioned issues of
sensitization. To determine cross-sensitization effects between the cannabinoid and dopamine
systems, a subset of mice was administered the dopamine reuptake blocker cocaine during
amperometric recordings. Overall, this study examines the effects of chronic cannabinoid
activation (by both indirect and direct agonists) on the mesolimbic dopamine system and the way
this pathway responds to a dopamine agonist.
Methods
All procedures have been approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Memphis and were also aligned with those outlined in The Public
Health Service Policy on Humane Care and Use of Laboratory Animals (National Institutes of
Health 2012) and the Guidelines for the Care and Use of Mammals in Neuroscience and
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Behavioral Research (National Research Council 2003). The current study was split into two
major experiments. In the first, mice underwent chronic, seven-day drug treatment, the OF on
day one and day seven, and then in vivo FPA on day eight. In the second, mice underwent CPP
for eight days followed by two-bottle choice test between saccharin and water for five days.
Animals
Fifty-four, male C57BL/6J mice (n = 54) for the first experiment and 27, male C57BL/6J
mice (n = 27) for the second experiment were obtained from Jackson Laboratory (Bar Harbor,
ME) and were housed 2-5 per cage in 18.5 x 29.5 cm polycarbonate Generic State Microisolators
with Sani-Chips bedding (P.J. Murphy Forest Products, Montville, New Jersey). Food and water
were available ad libitum. Mice were housed in a temperature-controlled room (21 ± 1° C) with
a 12 h light: 12 h dark cycle. At the time of drug treatments and experiments, mice were 3 to 5
months old (adults).
Chronic Drug Treatments
For the first experiment, mice were randomly selected to receive one of three chronic
treatments. Chronic drug treatments consisted of one i.p. injection per day for seven days of
either AA-5-HT (2.5 mg/kg, n = 19), ACEA (1.0 mg/kg, n = 15), or vehicle (n = 20) all acquired
from Sigma Aldrich (St. Louis, MO). This amount of AA-5-HT reflects the dose that was
utilized by Micale et al. (2009) and caused behavioral changes related to anxiety in both B6 and
Swiss mice. This amount of ACEA reflects the dose that was utilized by Rutkowska and
Jachimczuk (2004) and Freels, Lester, and Cook (2019), which trended to or moderately caused
behavioral changes related to stress. On the eighth day, during in vivo FPA, mice received an i.p.
injection of either AA-5-HT (2.5 mg/kg, n = 13), ACEA (1.0 m/kg, n = 9), cocaine (10.0 mg/kg,
n = 17) or vehicle (n = 15). As can be seen in Table 1, the ten total groups encompassed AA-5-
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HT-AA-5-HT (n = 7), AA-5-HT-vehicle (n = 6), AA-5-HT-cocaine (n = 6), ACEA-ACEA (n =
5), ACEA-vehicle (n = 5), ACEA-cocaine (n = 5), vehicle-AA-5-HT (n = 6), vehicle-ACEA (n =
4), vehicle-vehicle (n = 4), and vehicle-cocaine (n = 6) where the first drug represents that given
during behavioral testing and the second drug represents that given during in vivo FPA. For, the
second experiment, mice were also randomly selected to receive one of three chronic treatments.
Chronic drug treatments consisted of one i.p. injection every other day for six days, two days off,
then five days of either AA-5-HT (2.5 mg/kg, n = 9), ACEA (1.0 mg/kg, n =9), or vehicle (n = 9)
all acquired from Sigma Aldrich (St. Louis, MO). To minimize outside anxiogenic variables,
drug treatments were administered by the same person, at the same time each day.
Open Field
For the first experiment, mice were tested in the OF chamber twice, once on the first day
of the chronic drug treatment and again on the seventh day of treatment. On test day, each
mouse was placed in a single holding cage inside a sound attenuated cabinet in the testing room
for 45 minutes in order to habituate the mouse. At the beginning of each OF test, the mouse was
placed in the center of the OF chamber. The OF apparatus was a HamiltonKinder SmartFrame™
(HamiltonKinder, Poway, CA) with a clear Plexiglass insert with dimensions of 24.13 cm x
45.72 cm, a 4 x 8 photo beam strip, and a 4 x 8 photo beam rearing attachment. During the
session, software (MotorMonitor verison 4.14, HamiltonKinder, Poway, CA) tracked the time
spent in the central area, time spent outside of the central area, rearing, and total distance
travelled. The central area specified in the software’s zone map function was a of 9 cm x 10 cm
space positioned 4.5 cm from the left and right walls and 15 cm from the front and back walls of
the chamber. After a 20 min baseline movement assessment, the mouse received an i.p.
injection of the assigned chronic treatment (AA-5-HT, ACEA, or vehicle) and testing continued
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for 90 min post-injection. At the end of the test, each mouse was returned to its home cage in the
mouse colony. The OF chamber was then cleaned with 10% isopropyl alcohol and allowed to
dry after each trial.
Dopamine Recordings
For the first experiment, on the eighth day of the chronic drug treatments, all mice
underwent stereotaxic surgery for the measurement of dopamine transmission using in vivo FPA.
Mice were permanently anaesthetized with urethane (1.5 g/kg, i.p.). The dose of which was split
into two i.p. injections separated by 10 min. Fifteen min following the second injection, mouse
anesthesia was assessed through eye blink, mild tail pinch, and mild foot pinch reflexes. Mice
were mounted into a stereotaxic frame, and their body temperature was kept at approximately
37°C. A stimulating electrode (Rhodes Medical Co., Summerland, CA) was placed into the left
VTA (coordinates in mm from bregma: AP -3.3, ML +0.3, and DV -4.0 from dura; Paxinos &
Franklin, 2001). A Ag/AgCl reference and stainless-steel auxiliary electrode combination was
placed on contralateral cortical tissue -2.0 mm to bregma, and a carbon fiber recording electrode
(500 um length x 7 um o.d.; Union Carbide, North Seadrift, TX) was positioned in the left NAc
(coordinates in mm from bregma: AP +1.5, ML +1.0, and DV -4.0 from dura; Paxinos &
Franklin 2001). A fixed +0.8V current was continuously applied to the recording electrode,
which oxidized the dopamine. The change in current due to the oxidation of dopamine was
monitored by the electrometer (filtered at 50 Hz) 10,000 times per second.
Stimulation parameters varied depending on the aspect of dopamine transmission being
measured. Initially, while establishing a baseline response, the stimulation protocol consisted of
20 monophasic 0.5 ms duration pulses (800 µAmps) at 50 Hz. DAR sensitivity was assessed by
applying a pair of test stimuli (T1 and T2, each 10 pulses at 50 Hz with 10 sec between T1 and
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T2) to the VTA every 30 sec (Fielding et al., 2013, Holloway et al., 2018, and Mittleman et al.,
2011). Six sets of conditioning pulses (1, 5, 10, 20, 40, and 80; 0.5 ms pulse duration at 15 Hz)
were delivered prior to T2 such to leave 0.3 s between the end of the conditioning pulse train and
initiation of T2. DAR-mediated inhibition of evoked dopamine efflux was expressed in terms of
the change in the amplitude of T2 with respect to T1 for each set of conditioning pulses; low-tohigh DAR sensitivity was represented as low-to-high percent inhibition of evoked dopamine
efflux (i.e. high sensitivity results in lower amplitude of T2 relative to T1).
Upon completion of the autoreceptor sensitivity test, stimulation parameters were reset to
20 pulses at 50 Hz every 30 sec. Following 5 min of baseline dopamine efflux recording, each
mouse was given a drug challenge via an i.p. injection of AA-5-HT (2.5 mg/kg), ACEA (1.0
mg/kg), cocaine (10 mg/kg) or vehicle. See Table 1 or the chronic drug treatments subsection
for the experimental groups. Dopamine recordings continued for 90 min post drug challenge for
AA-5-HT, ACEA, and vehicle groups and for 60 min post drug challenge for cocaine groups.
After the recordings were complete, direct anodic current of 100 µAmps was applied to the
stimulating electrode for 10 s to create an iron deposit, which marked the electrode’s position.
Mice were euthanized via an intracardial injection of urethane (0.345 g/mL). Brains were
removed and stored in 30% sucrose / 10% formalin solution with 0.1% potassium ferricyanide.
Coronal sections of each brain were sliced at -30°C using a cryostat, and electrode placements
were identified using a light microscope and marked on coronal diagrams (Paxinos & Franklin,
2001). Following the experiment, in vitro electrode calibration occurred by recording in
solutions of dopamine (0.2 µM – 1.2 µM) via a flow injection system (Dugast, Suaud-Chagny, &
Gonon, 1994), which allowed for the conversion of current measurements to dopamine
concentrations.
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Conditioned Place Preference
For the second experiment, mice were tested in conditioned place preference (CPP)
chambers that were counterbalanced across conditions. On test day, each mouse was placed in a
single holding cage inside a sound attenuated cabinet in the testing room for 45 min in order to
habituate the mouse. On the first day, the mouse was placed into the front part of the
HamiltonKinder SmartFrame™ (HamiltonKinder, Poway, CA) with an insert to divide the OF
into two halves measuring 21.84 cm x 22.23 cm each and a doorway between them measuring
6.99 cm (width) x 8.89 cm (height). The walls of the chamber were covered with either vertical
or horizontal black and white bars each measuring 2.54 cm thick. The vertical bars side was
paired with Sani-chips bedding (P.J. Murphy Forest Products, Montville, New Jersey), and the
horizontal bars side was paired with So Phresh Natural Softwood bedding (Petco Animals
Supplies, San Diego, CA). The beddings were covered by a black grating. The test occurred for
30 min. On day two to seven, the mouse was given an i.p. injection of either the assigned drug
treatment or vehicle, starting with drug treatment and alternating each day. The mouse was then
placed into a specific side of the CPP chamber where the other side was blocked off by a black,
opaque insert over the doorway. The side in which the mouse was placed was alternated
depending on whether the mouse was receiving the drug treatment or vehicle on that day. The
test occurred for 30 min. On the eighth day, the mouse was returned to the CPP chamber with
the door insert removed for 30 min. At the end of each test, the mouse was returned to its home
cage in the mouse colony. The OF chamber was then cleaned with 10% isopropyl alcohol and
allowed to dry after each trial.
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Two-Bottle Choice Test
Additionally, for the second experiment, one day following CPP testing, mice underwent
two-bottle choice test for saccharin or water preference. Saccharin is a non-satiating sweetener
for which animals develop a preference (Collier & Novell, 1967; Haussmann, 1933; Sheffield &
Robey, 1950). A reduction in the preference ratio for saccharin during this test is indicative of
anhedonia (Liu et al., 2018). Mice were weighed and then deprived of water for 12 hours.
Following water deprivation, mice were injected with AA-5-HT (2.5 mg/kg, n = 9), ACEA (1.0
mg/kg, n = 9), or vehicle (n = 9). One bottle of saccharin (0.001 g/ml water) and one bottle of
water were weighed and fixed onto a second cage with the same dimensions of the home cage.
Then, mice were placed individually into the cages for 2 h to examine drinking preference. After
the 2 h test, mice were returned to the home cage, and the bottles were weighed again. The first
day was considered a trial, days two to six were utilized for examining group differences.
Design and Statistical Analyses
For the first experiment, data was analyzed in two separate sets, one for behavioral data
and one for electrochemical data. OF data was analyzed using three-way ANOVAs for day x
block x treatment effects, which includes distance travelled, rears, and percent time in center.
Significant treatment differences indicated by p < 0.05 were further explored using GamesHowell post-hoc tests when appropriate. Electrochemical data were broken down into
autoreceptor sensitivity, baseline dopamine recordings, and drug challenge recordings.
Dopamine oxidation current recordings were used to quantify VTA stimulation-induced
dopamine release in the and NAc by extracting data points occurring between 0.25 s pre- and 10
s post-stimulation at 10 min intervals (11 total intervals for AA-5-HT, ACEA, and vehicle and 7
total intervals for cocaine). Dopamine autoreceptor sensitivity was assessed by applying a pair
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of test stimuli (T1 and T2), which were each 10 pulses at 50 Hz with 10 s between them to the
VTA every 30 s. In between the two test stimuli, for every other set of test stimuli, sets of 1, 5,
10, 20, 40, and 80 conditioning pulses of .5 ms at 15 Hz were delivered prior to T2 such that
there was 0.3 s between the end of the conditioning pulse train and initiation of T2. These
stimulation parameters are like previous studies exploring dopamine dynamics (Fielding et al.,
2013; Holloway et al., 2018; Mittleman et al., 2011). Dopamine half-life (in seconds) was
calculated using the formula: (peak release time - baseline return time) / 2 (Mittleman et al.,
2011). Data from in vitro calibrations of recording electrodes were used to convert the mean
change in dopamine oxidation current (nA) to a mean concentration (μM). Change in the
concentration of dopamine release was expressed as an average percent change relative to
baseline release (pre-drug = 100%). For the autoreceptor sensitivity test, a two-way repeated
measures ANOVA was used to assess the impact of pretreatment and amount of pre-pulses on
percent inhibition. For the baseline and drug challenge, a two-way repeated measures ANOVA
was used to assess the impact of treatment and time point on percent change in dopamine release
and percent change in dopamine half-life in the NAc of B6 mice. A one-way ANOVA was used
to test the effects of treatment on percent change in dopamine release at each time point.
Significant treatment differences indicated by p < .05 were further explored using Tukey’s HSD
post-hoc or Games-Howell post-hoc tests when appropriate.
For the second experiment, the two sets of behavioral data were analyzed separately. For
CPP, bias on the first day was analyzed by a one samples t-test compared to 900 s. Time spent
on the drug paired side on day one was subtracted from the time spent on the drug paired side on
day one, and the difference was analyzed by a one-way ANOVA. Entries into the drug paired
side on day one was subtracted from entries into the drug paired side on day eight, and the
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difference was analyzed by a one-way ANOVA. Distance travelled (cm) on drug paired days
was analyzed by a two-way ANOVA. For the two-bottle choice test, saccharin consumed (g)
was divided by mouse weight (kg), and the quotient was analyzed by a two-way ANOVA.
Saccharin consumed (g) as a percent of total liquid consumed (g) was analyzed by a two-way
ANOVA.
Results
In this study, the OF and FPA were utilized to explore the profiles of indirectly and
directly agonizing the cannabinergic system through differences in locomotor activity and
dopaminergic responses in the NAc via stimulation in the VTA. Then, CPP and two-bottle
choice test were utilized to explore the profiles of indirectly and directly agonizing the
cannabinergic system with regards to addiction potential and anhedonia respectively.
Open Field
Locomotor activities assessed in the OF included distance travelled (cm), rearing, and
percent time spent in center. Baseline locomotor activity was assessed in two 10 min blocks per
day. As can be seen in Figure 1A, there was not a main effect of pretreatment on distance
travelled, F(2,51) = 0.46, p = .67, ηp2 = .02. There was not a day x pretreatment (F(2,51) = 0.10,
p = .91, ηp2 = .004), block x pretreatment (F(2,51) = 1.05, p = .357, ηp2 = .04), or day x block x
pretreatment (F(2,51) = 2.69, p = .078, ηp2 = .10) interaction effect on distance travelled. As can
be seen in Figure 1B, there was not a main effect of pretreatment on rears, F(2,51) = 0.57, p .57,
ηp2 = .02. There was not a day x pretreatment (F(2,51) = 0.64, p = .53, ηp2 = .02), block x
pretreatment (F(2,51) = 2.69, p = .077, ηp2 = .10), or day x block x pretreatment (F(2,51) = 0.92,
p = .41, ηp2 = .04) interaction effect on rears. As can be seen in Figure 1C, there was not a main
effect of pretreatment on percent time in the center, F(2,51) = 0.89, p = .42, ηp2 = .03. There was
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not a day x pretreatment (F(2,51) = 1.08, p = .35, ηp2 = .04), block x pretreatment (F(2,51) =
1.37, p = .26, ηp2 = .05), or day x block x pretreatment (F(2,51) = 0.29, p = .75, ηp2 = .01)
interaction effect on percent time in the center.
During the drug challenge in the OF on the first and seventh day, locomotor activities
were recorded in 10 min blocks. Distance travelled (cm) in the OF was analyzed across the three
pretreatment conditions. As can be seen in Figure 2A, the effect of pretreatment on distance
travelled approached significance, F(2,51) = 2.75, p = .07, ηp2 = .10. Games-Howell post-hoc
test revealed that ACEA pretreated mice (M = 129.95, SE = 15.25) travelled significantly less
distance than vehicle pretreated mice (M = 208.14, SE = 23.52), p = .02. There was not a day x
pretreatment interaction effect (Pillai’s trace = 0.02, F(2,51) = 0.64, p = .53, ηp2 = .02) on
distance travelled. There was not a block x pretreatment interaction effect (Pillai’s trace = 0.32,
F(16,90) = 1.05, p = .41, ηp2 = .16) on distance travelled. There was not a day x block x
pretreatment interaction effect (Pillai’s trace = 0.226, F(16,90) = 1.47, p = .13, ηp2 = .21) on
distance travelled.
Rearing behavior in the OF was analyzed across the three pretreatment conditions. As
can be seen in Figure 2B, there was a main effect of pretreatment on rears, F(2,51) = 4.53, p =
.02, ηp2 = .15. Games-Howell post-hoc test revealed that ACEA pretreated mice (M = 5.50, SE =
0.04) reared significantly less than vehicle pretreated mice (M = 11.51, SE = 0.05), p = .01.
There was not a day x pretreatment interaction effect (Pillai’s trace = 0.03, F(2,51) = 0.90, p =
.41, ηp2 = .03) on rears. There was not a block x pretreatment interaction effect (Pillai’s trace =
.03, F(16,90) = 1.03, p = .43, ηp2 = .15) on rears. There was not a day x block x pretreatment
interaction effect (Pillai’s trace = 0.30, F(16,90) = 0.99, p = .48, ηp2 = .15) on rears.
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Percent time in the center was analyzed across the three pretreatment conditions. As can
be seen in Figure 2C, there was not a main effect of pretreatment on percent time spent in the
center, F(2,51) = 2.01, p = .14, ηp2 = .07. There was not a day x pretreatment interaction effect
(Pillai’s trace = 0.07, F(2,51) = 1.96, p = .15, ηp2 = .07) on percent time in center. There was not
a block x pretreatment interaction effect (Pillai’s trace = 0.18, F(16,90) = 0.51, p = .92, ηp2 = .09)
on percent time in center. There was not a day x block x pretreatment interaction effect (Pillai’s
trace = 0.35, F(16,90) = 1.18, p = .30, ηp2 = .17) on percent time in center.
Dopamine Autoreceptor Sensitivity
DAR sensitivity was analyzed across pretreatment conditions as previously described.
As seen in Figure 3, there was not a main effect of pretreatment on autoreceptor sensitivity,
F(2,50) = 1.66, p = .20, ηp2 = .06. There was a main effect of amount of pre-pulses on
autoreceptor sensitivity, Pillai’s trace = 0.77, F(6,45) = 25.30, p < .001, ηp2 = .77. There was not
an amount of pre-pulses x pretreatment interaction effect (Pillai’s trace = 0.18, F(12,92) = 0.76,
p = .70, ηp2 = .09) on autoreceptor sensitivity.
Baseline Dopamine Recordings
Baseline dopamine release (µM) was analyzed across the three pretreatment conditions.
As can be seen in Figure 4, there was a main effect of pretreatment on baseline dopamine
release, F(2,51) = 3.21, p = .049, η2 = .11. Tukey’s post-hoc test revealed that ACEA pretreated
mice’s baseline dopamine release (M = 0.18, SE = 0.01) was diminished in comparison to
vehicle pretreated mice’s baseline dopamine release (M = 0.29, SE = 0.01), p = .04. Baseline
dopamine half-life was analyzed across the three pretreatment conditions. There was not a main
effect of pretreatment on baseline dopamine half-life, F(2,51) = 0.66, p = .52, η2 = .02.
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Dopamine Recordings Following Drug Challenge
Drug Challenge: AA-5-HT
During dopamine recordings, a subset of the mice pretreated with AA-5-HT or vehicle
received an i.p. drug challenge of either AA-5-HT (n = 7 and 6, respectively per pretreatment) or
vehicle (n = 5 and 4, respectively per pretreatment). Percent change of dopamine release and
half-life (with baseline dopamine release and half-life being 100%) were analyzed at 10 min
intervals for 90 min post injection. As can be seen in Figure 5A, there was not a main effect of
pretreatment on percent change in dopamine release, F(1,19) = 0.67, p = .42, ηp2 = .03. There
was not a main effect of drug challenge on percent change in dopamine release, F(1,19) =
0.00024, p = .99, ηp2 = .00. There was not a pretreatment x drug challenge interaction effect
(F(1,19) = 0.12, p = .73, ηp2 = .01) on percent change in dopamine release. There was not a time
point x pretreatment interaction effect (Pillai’s trace = 0.57, F(9,11) = 1.62, p = .22, ηp2 = .57) on
percent change in dopamine release. There was not a time point x drug challenge interaction
effect (Pillai’s trace = 0.45, F(9,11) = 0.99, p = .50, ηp2 = .45) on percent change in dopamine
release. There was not a time point x pretreatment x drug challenge interaction effect (Pillai’s
trace = 0.45, F(9,11) = 0.23, p = .98, ηp2 = .16) on percent change in dopamine release.
Percent change in dopamine half-life was analyzed across AA-5-HT and vehicle
pretreated mice. As can be seen in Figure 5B, there was not a main effect of pretreatment on
percent change in dopamine half-life, F(1,19) = 0.39, p = .54, ηp2 = .02. There was not a main
effect of drug challenge on percent change in dopamine half-life, F(1,19) = 3.25, p = .09, ηp2 =
.15. There was not a pretreatment x drug challenge interaction effect (F(1,19) = 0.10, p = .75,
ηp2 = .01) on percent change in dopamine half-life. There was not a time point x pretreatment
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interaction effect (Pillai’s trace = 0.38, F(9,11) = 0.75, p = .66, ηp2 = .38) on percent change in
dopamine half-life. There was not a time point x drug challenge interaction effect (Pillai’s trace
= 0.39, F(9,11) = 0.77, p = .65, ηp2 = .39) on percent change in dopamine half-life. There was
not a time point x pretreatment x drug challenge interaction effect (Pillai’s trace = 0.60, F(9,11)
= 1.82, p = .17, ηp2 = .60) on percent change in dopamine half-life.
Drug Challenge: ACEA
During dopamine recordings, a subset of the mice pretreated with ACEA or vehicle
received an i.p. drug challenge of either ACEA (n = 5 and 4, respectively per pretreatment) or
vehicle (n = 5 and 4, respectively per pretreatment). Percent change of dopamine release and
half-life (with baseline dopamine release and half-life being 100%) were analyzed at 10 min
intervals for 90 min post injection. Percent change in dopamine release was analyzed across
ACEA and vehicle pretreated mice. As can be seen in Figure 6A, there was not a main effect of
pretreatment on percent change in dopamine release, F(1,14) = 2.09, p = .17, ηp2 = .13. The main
effect of drug challenge on percent change in dopamine release (F(1,14) = 4.59, p = .05, ηp2 =
.25) approached significance. There was not a pretreatment x drug challenge interaction effect
(F(1,14) = 1.55, p = .23, ηp2 = .10) on percent change in dopamine release. There was not a time
point x pretreatment effect (Pillai’s trace = 0.54, F(9,6) = 0.79, p = .64, ηp2 = .54) on percent
change in dopamine release. There was not a time point x challenge drug interaction (Pillai’s
trace = 0.78, F(9,6) = 2.41, p = .15, ηp2 = .78) on percent change in dopamine release. There was
a time point x pretreatment x challenge drug interaction (Pillai’s trace = 0.90, F(9,6) = 6.07, p =
.02, ηp2 = .90) on percent change in dopamine release.
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Percent change in dopamine half-life was analyzed across ACEA and vehicle pretreated
mice. As can be seen in Figure 6B, there was not a main effect of pretreatment on percent change
in dopamine half-life, F(1,19) = 0.65, p = .44, ηp2 = .04. There was not a main effect of drug
challenge on percent change in dopamine half-life, F(1,19) = 3.77, p = .073, ηp2 = .21. There
was not a pretreatment x drug challenge interaction effect (F(1,19) = 0.57, p = .46, ηp2 = .04) on
percent change in baseline dopamine half-life. There was not a time point x pretreatment
interaction effect (Pillai’s trace = 0.60, F(9,6) = 1.00, p = .52, ηp2 = .60) on percent change in
baseline dopamine half-life. There was not a time point x drug challenge interaction effect
(Pillai’s trace = 0.76, F(9,6) = 0.78, p = .19, ηp2 = .76) on percent change in dopamine half-life.
There was not a time point x pretreatment x drug challenge interaction effect (Pillai’s trace =
0.61, F(9,6) = 1.04, p = .50, ηp2 = .61) on percent change in baseline dopamine half-life.
Drug Challenge: Cocaine
During dopamine recordings, a subset of the mice pretreated with AA-5-HT, ACEA, or
vehicle received an i.p. drug challenge of cocaine (n = 6, 5, and 6 per pretreatment group
respectively). Percent change of dopamine release (with baseline dopamine release being 100%)
was analyzed at 10 min intervals for 60 min post injection. As can be seen in Figure 7A, there
was not a main effect of pretreatment on percent change in dopamine release, F(2,14) = 1.21, p =
.33, ηp2 = .15. There was not a time point x pretreatment interaction effect (Pillai’s trace = 0.98,
F(12,20) = 1.61, p = .17, ηp2 = .49) on percent change in dopamine release.
Percent change in dopamine half-life was analyzed across mice receiving the drug
challenge of cocaine. As can be seen in Figure 7B, there was not a main effect of pretreatment
on percent change in dopamine half-life, F(2,14) = 2.99, p = .08, ηp2 = .30. There was a
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significant time point x pretreatment interaction effect (Pillai’s trace = 1.20, F(12,20) = 2.50, p =
.034, ηp2 = .60) on percent change in dopamine half-life. There was a near significant main
effect of pretreatment (Welch’s F(2,6.68) = 4.77, p = .05, ω2 = 0.31) on percent change in
dopamine half-life at 10 min post-injection. Games-Howell post-hoc test revealed ACEA
pretreated mice’s percent change in dopamine half-life (M = 273.32, SE = 28.11) was
significantly increased in comparison to vehicle (M = 170.81, SE = 18.43), p = .04. There was a
near significant main effect of pretreatment (Welch’s F(2,8.13) = 4.42, p = .05, est. ω2 = 0.29)
on percent change in dopamine half-life at 20 min post-injection. Games-Howell post-hoc test
revealed ACEA pretreated mice’s percent change in dopamine half-life (M = 346.19, SE = 26.77)
was significantly increased in comparison to vehicle (M = 240.04, SE = 21.68), p = .04.
Stereotaxic Placement of Electrodes
As can be seen in Figure 8, following amperometry experiments, the placement of
stimulating electrodes (n = 54) and recording electrodes (n = 54) were determined by examining
lesioned regions in sectioned mouse brains. The positions of stimulating electrodes were
localized within the anatomical region of the VTA spanning -3.08 to -3.52 mm AP from bregma
and -4.0 to -5.0 mm DV from dura, and the positions for the recording electrodes were localized
within the anatomical region of the NAc spanning +1.54 to + 1.34 mm AP from bregma and -4.0
to -5.0 mm DV from dura.
Conditioned Place Preference
During CPP, mice could explore the entire chamber for 30 min on the first day. The mice
travelled a similar amount of time on the drug paired side (M = 929.98 s, SE = 19.11) as
compared to the expected for each side (900 s), t(26) = 1.57, p = .05. On the eighth day, mice
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could explore the entire chamber again to ascertain a preference for either side. Time spent on
the drug paired side for day one was subtracted from time spent on the drug paired side for day
eight. As can be seen in Figure 9A, there was not a main effect of pretreatment (F(2,26) = 1.10,
p = .35, ηp2 = .08) on time spent on the drug paired side. Additionally, entries to the drug paired
side were recorded. Entries into the drug paired side for day one was subtracted from entries into
the drug paired side for day eight. As can be seen in Figure 9B, there was not a main effect of
pretreatment (F(2,26) = 0.02, p = .98, ηp2 = .00) on entries into the drug paired side.
Distance travelled was recorded on the drug paired days where mice were given either an
i.p. injection of AA-5-HT, ACEA, or vehicle and confined to a single side of the chamber. As
can be seen in Figure 10, there was not a main effect of drug on distance travelled on drug
paired days, F(2,24) = 1.36, p = .28, ηp2 = .10. There was not a day x drug treatment interaction
effect (F(4,48) = 0.74, p = .57, ηp2 = .06) on distance travelled on drug paired days.
Two-Bottle Choice Test
For the two-bottle choice test, saccharin consumed (g) was divided by mouse weight
(kg). There was not a main effect of treatment on body weight, F(2,24) = 0.05, p = .95, ηp2 = .00.
There was no day x treatment interaction effect (Pillai’s trace = 0.46, F(8,44) = 1.65, ηp2 = .23)
on body weight. As can be seen in Figure 11A, there was not a main effect of treatment on
saccharin consumed over body weight, F(2,24) = 0.18, p = .83, ηp2 = .02. There was not a day x
treatment interaction effect (Pillai’s trace = 0.77, F(8,44) = .54, p = .84, ηp2 = .09) on saccharin
consumed over body weight. Additionally, preference for saccharin was calculated as saccharin
consumption (g) as a percent of total liquid consumed (g). As can be seen in Figure 11B, there
was not a main effect of treatment on saccharin as a percent of total liquid consumed, F(2,24) =
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.004, p = .99, ηp2 = .00. There was not a day x treatment interaction effect (F(8,96) = .68, p =
.71, ηp2 = .05) on saccharin as a percent of total liquid consumed.
Discussion
The cannabinergic system is a target for the development of potential anxiolytic drugs.
The mesolimbic dopamine pathway plays integral roles in addiction and anxiety. Therefore, the
development of anxiolytic pharmaceuticals necessitates exploring the dopaminergic alterations in
response to their administration. The current study aims to explore the addictive potential of
indirectly or directly modulating cannabinergic signaling via AA-5-HT or ACEA administration
respectively.
In the OF, AA-5-HT administration did not significantly alter locomotor activities
including distance travelled, rearing, or percent time in the center. The lack of change in
distance travelled and rearing may be indicative of a non-addictive profile for this drug. Previous
research has shown that AA-5-HT and AACOCF3 (an FAAH inhibitor) did not alter locomotor
activity in the OF (Freels, Lester, & Cook, 2019; Rutkowska, Jamontt, & Gliniak, 2006).
However, with no change in percent time in center, this drug also did not appear to have
anxiolytic potential in this study. This may have occurred due to the choice of strain (B6) over a
more anxious strain and due to the choice of test for anxiety as moderate anxiolytic effects were
found in BCJ mice and in the EPM (Freels, Lester, & Cook, 2019; Micale et al., 2009). Further
research could explore the anxiolytic potential of this drug in more anxious mice or more
anxiogenic tests. ACEA significantly decreased the rearing frequency of mice but did not alter
distance travelled or percent time in center. Previous research has shown that CB1R agonists do
not alter locomotor activities in the OF except for suppressing rearing behavior (Freels, Lester, &
Cook, 2019; Järbe, Andrzejewski, & DiPatrizio, 2002; Rutkowska, Jamontt, & Gliniak, 2006).
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Future research could address the length of the OF test as it may have been too long as the mice
moved infrequently between 70 and 90 mins in the OF. An altered paradigm such as a shorter
OF test or altered design such as the EPM or forced swim test may reveal anxiolytic effects.
However, the mouse strain and OF contexts of the current study did not provide behaviors
related to anxiety or addiction.
During FPA, AA-5-HT did not significantly alter dopamine dynamics at baseline, in
autoreceptor sensitivity, or during drug challenge. Previous research has shown AA-5-HT to
attenuate evoked dopamine release (Freels, Lester, & Cook, 2019). Though, these results also
support a lack of reinforcing effects of AA-5-HT administration via not increasing dopamine in
the NAc, which coincides with previous studies exploring FAAH inhibition (Freels, Lester, &
Cook, 2019; Gamage et al., 2015; Justinová et al., 2015; Murillo-Rodríguez, Palomero-Rivero,
Millán-Aldaco, & Di Marzo, 2013; Valchou, Nomikos, & Pangais, 2006). AA-5-HT
pretreatment did not alter dopamine dynamics in response to a cocaine drug challenge. Previous
research has shown cocaine and URB597 pretreatment followed 24 h later by a cocaine drug
challenge increased percent change in dopamine release in the NAc core (Mereu et al., 2013).
Thus, the dual FAAH inhibition and TRPV1 blocking action of AA-5-HT, the chronic
administration, or the lack of DAT sensitization due to a single dose of cocaine, may have
attenuated the alterations in dopamine signaling previously shown during a cocaine drug
challenge in the NAc of mice. Therefore, AA-5-HT treatment did not elicit a dopaminergic
profile associated with abuse and addiction.
ACEA significantly reduced baseline dopamine release, altered drug challenge evoked
dopamine release in a pretreatment- and time-dependent manner, and, through pretreatment,
enhanced cocaine drug challenge induced increases in dopamine half-life. A previous study
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from our laboratory found ACEA administration attenuated evoked dopamine release in the NAc
utilizing in vivo FPA (Freels, Lester, & Cook, 2019). Additional studies found similar results
utilizing direct CB1R agonists with regards to the reduction in dopamine efflux utilizing fast-scan
cyclic voltammetry (Cheer, Wassum, Heien, Phillips, & Wightman, 2004; O’Neill, EversDonnelly, Nicholson, O’Boyle, & O’Connor, 2009). ACEA pretreatment increased dopamine
half-life in the NAc during the cocaine drug challenge. This may be mediated through
cannabinoid driven alterations in DAT populations or binding affinities. WIN55,212-2
administration decreased dopamine uptake and increased dopamine clearance time (Price et al.,
2006). Additionally, chronic, 20-day administration of WIN55,212-2 reduced DAT protein
levels in the striatum and DAT mRNA levels and binding in the VTA (Perdikaris, Tsarouchi,
Fanarioti, Natsaridis, Mitsacos, & Giompres, 2018). CB1R antagonism decreased cocaine
induced dopamine transient frequency and dopamine transients’ amplitude in the NAc in a 2AG-dependent manner, suggesting an eCB- and CB1R-dependent inhibition of dopamine
signaling (Cheer et al., 2007; Wang, Treadway, Covey, Cheer & Lupica, 2015). Cocaine and
rimonabant pretreatment followed 24 h later by a cocaine drug challenge blocked the percent
increase in dopamine release following a cocaine drug challenge in the NAc core (Mereu et al.,
2013). Thus, CB1R agonist pretreatment alters baseline dopamine release, DAT expression
and, in response to a cocaine drug challenge, NAc dopamine dynamics. Chronic administration
of direct CB1R agonists may interfere with the efficacy of other drugs that work on the dopamine
system such as amphetamines that bind to and reverse DAT function and alter DAT trafficking
(Robertson, Matthies, & Galli, 2009). Further research could explore DAT expression in
response to a CB1R agonist pretreatment and cocaine drug challenge through Western blot,
radioligand binding assay, and autoradiography. Therefore, ACEA treatment also does not elicit
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a dopaminergic profile associated with abuse and addiction but may sensitize the mesolimbic
dopamine pathway to the effects of cocaine and other dopamine modulating drugs of abuse.
During CPP, mice did not develop a CPP or CPA for either AA-5-HT or ACEA.
Previous research has shown that Wistar rats, Sprague-Dawley rats and B6 mice in standard
housing conditions do not have a CPP for AM404 (an inhibitor of AMT), AM404 except at 10.0
mg/kg, or SBFI26 (an inhibitor of FABP5 and FABP7) respectively (Bortolato et al., 2006;
Scherma et al., 2012; Thanos et al., 2016). Direct CB1R agonist administration can produce
CPP, no preference, or CPA in a drug and dose dependent manner where THC typically causes a
CPP under 5.0 mg/kg and a CPA at 5.0 mg/kg or higher but WIN55,212-2 has variable results
where a CPP occurred under 1.0 mg/kg, no preference occurred from 1.0 mg/kg to 3.0 mg/kg,
and a CPA occurred from 0.25 mg/kg to 2.5 mg/kg (Murray & Bevins, 2010; Panagis, Mackey,
& Vlachou, 2014). Therefore, indirectly and directly agonizing the cannabinergic system can
lead to CPP, but the doses in the current study, which were chosen due to their anxiolytic
potential, did not, which suggests these doses are not rewarding or aversive in the current
paradigm.
During the two-bottle choice test, mice treated with either AA-5-HT or ACEA did not
develop a preference or aversion for saccharin. CP55940, URB597, and rimonabant had no
effects on saccharin preference alone, but chronic mild stress-induced reductions in sucrose
preference were attenuated by CP55940 or URB597 and enhanced by rimonabant (Bortolato et
al., 2007; Rademacher & Hillard, 2007). This suggests that indirectly and directly agonizing the
cannabinoid system does not alter preference for sweet rewards alone but can modify stressinduced alterations in preference. Therefore, exploring preference for saccharin following both
cannabinoid administration and stress may further the potential use of these drugs as anxiolytics.
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However, CP55940 increased progressive ratio responding for Ensure where rimonabant reduced
it, suggesting the cannabinergic system still plays a role in the wanting of sweet rewards (Ward
& Dykstra, 2005). AA-5-HT and ACEA administration did not alter saccharin preference,
indicating these drugs do not elicit reward- or anhedonia-related behaviors.
Cross-modulation between neurotransmission systems can impact the efficacy and offtarget effects of posited drugs. The current study explored the interplay between the
cannabinergic system and dopaminergic system through the administration of AA-5-HT and
ACEA. Through this study’s paradigms, AA-5-HT did not modulate mesolimbic dopamine
neurotransmission, but ACEA decreased baseline dopamine release, altered dopamine
transmission during the drug challenge, and enhanced cocaine induced increases in dopamine
half-life in the NAc. Cannabinoid induced increases in DRs and decreases in CB1Rs could lead
to a system primed for dysregulation and super-sensitization of the dopamine system due to
increasing DR populations and decreasing GABAAR modulation, which could prime the brain,
especially the mesolimbic dopamine pathway, for addiction to drugs that act on this pathway
(Ginovart et al., 2012; Morgan et al., 2014). The current study indicates this potential via
enhanced cocaine induced dopamine-half in the NAc following ACEA pretreatment. Therefore,
the dosage as well as other pharmaceuticals affecting the cannabinergic and dopaminergic
systems must be monitored to prevent deleterious off-target and side effects.
The cannabinergic system remains a target for the development of anxiolytic
pharmaceuticals. The current study found no evidence for an abuse potential for AA-5-HT or
ACEA with regards to alterations in locomotor activity in the OF or VTA stimulation evoked
dopamine efflux in the NAc. Overall, the current study did not find an abuse potential from
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indirectly or directly agonizing the cannabinergic system and suggests, with future research, that
the cannabinergic system may still be a potential target for the treatment of anxiety.
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Appendix A
Table 1
Dopamine Recording Drug Groups
Drug Pretreatment
FPA Drug Challenge
Vehicle
Vehicle
AA-5-HT
ACEA
Cocaine
AA-5-HT
Vehicle
AA-5-HT
Cocaine
ACEA
Vehicle
ACEA
Cocaine
Note. AA-5-HT = arachidonoyl serotonin; ACEA =
arachidonoyl-2’-chloroethylamide.
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n
4
6
4
6
6
7
6
5
5
5

A

B

C

Figure 1. Baseline locomotor activities in the OF averaged into 10 min blocks. There were no
baseline significant differences between vehicle, AA-5-HT (arachidonoyl serotonin), or ACEA
arachinoyol-2’-chloroethylamide) on (A) mean distance travelled ± SEMs, (B) mean rears ±
SEMs, or (C) mean percent time in center ± SEMs.
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A

B

C

Figure 2. Drug challenge locomotor activity in the OF averaged into 10 min blocks. (A) There
was a near significant difference in mean distance travelled ± SEMs. (B) There was a significant
difference in mean rears ± SEMs. (C) There was not a significant difference in percent time in
center ± SEMs. AA-5-HT = arachidonoyl serotonin, ACEA = arachidonyl-2’-chloroethylamide,
# indicates near significance at p < .075 and * indicates significance relative to vehicle pretreated
mice at p < .05.

50

Figure 3. Dopamine autoreceptor sensitivity. A representative response (A) and dopamine
autoreceptor sensitivity ± SEMs (B) following pre-pulses. Chronic pretreatment with either AA5-HT (arachidonoyl serotonin) or ACEA (arachidonyl-2’-chloroethylamide) did not alter
dopamine autoreceptor functioning in the NAc.
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A

B

Figure 4. Baseline dopamine results. Representative responses (A) and means ± SEMs (B) of
stimulation evoked dopamine release in the NAc following vehicle, AA-5-HT, or ACEA
pretreatment. AA-5-HT = arachidonoyl serotonin and ACEA = arachidonyl-2’-chloroethylamide.
* indicates a significant decrease relative to vehicle pretreatment at p < .05.
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A

B

Figure 5. Percent baseline dopamine release and half-life for AA-5-HT. (A) Pretreatment of
vehicle or AA-5-HT on percent baseline dopamine release presented as means ± SEMs. The
figure legend indicates the pretreatment drug then the drug challenge such that vehicle-vehicle
represents mice that received vehicle pretreatment and vehicle drug challenge. (B) Pretreatment
and drug challenge of vehicle or AA-5-HT on percent baseline dopamine half-life presented as
means ± SEMs. AA-5-HT = arachidonoyl serotonin and ACEA = arachidonyl-2’chloroethylamide.
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A

B

Figure 6. Percent baseline dopamine release and half-life for ACEA. (A) Pretreatment of vehicle
or ACEA on percent baseline dopamine release presented as means ± SEMs. The figure legend
indicates the pretreatment drug then the drug challenge such that vehicle-vehicle represents mice
that received vehicle pretreatment and vehicle drug challenge. (B) Pretreatment and drug
challenge of vehicle or ACEA on percent baseline dopamine half-life presented as means ±
SEMs. AA-5-HT = arachidonoyl serotonin and ACEA = arachidonyl-2’-chloroethylamide.
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A

B

Figure 7. Percent change in dopamine (A) release and (B) half-life following cocaine
administration (with baseline dopamine release set at 100%). Figure legends indicate the
pretreatment drug then the drug challenge such that vehicle-cocaine represents mice that received
vehicle pretreatment and cocaine drug challenge. AA-5-HT = arachidonoyl serotonin and ACEA
= arachidonyl-2’-chloroethylamide. + indicates p < .06.
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A

B

Figure 8. Representative coronal sections of the mouse brain (adapted from the atlas of Paxinos
& Franklin, 2001), with gray‐shaded areas indicating the placements (A) stimulating electrodes
in the ventral tegmental area (VTA) and amperometric recording electrodes in the (B) nucleus
accumbens (NAc). Numbers correspond to mm from bregma
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A

B

Figure 9. Time differences within and entries into the drug paired side. (A) Drug challenge on
time spent in the drug-paired side presented as day one subtracted from day eight. (B) Drug
challenge on entries into the drug paired side presented as day one subtracted from day eight.
AA-5-HT = arachidonoyl serotonin and ACEA = arachidonyl-2’-chloroethylamide.
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Figure 10. Drug challenge on distance travelled on drug-paired days. AA-5-HT = arachidonoyl
serotonin and ACEA = arachidonyl-2’-chloroethylamide.
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A

B

Figure 11. Drug challenge on saccharin preference when presented with one bottle of saccharin
and one of water. (A) Drug challenge on saccharin consumed over body weight. (B) Drug
challenge on saccharin consumed as a percent of total liquid consumed. AA-5-HT =
arachidonoyl serotonin and ACEA = arachidonyl-2’-chloroethylamide.
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